Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) EV-to-Revenue : 6.89 (As of May. 04, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Clinuvel Pharmaceuticals's enterprise value is $375.30 Mil. Clinuvel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $54.45 Mil. Therefore, Clinuvel Pharmaceuticals's EV-to-Revenue for today is 6.89.

The historical rank and industry rank for Clinuvel Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CLVLF' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.83 Med: 32.88 Max: 76.9
Current: 7.03

During the past 13 years, the highest EV-to-Revenue of Clinuvel Pharmaceuticals was 76.90. The lowest was 6.83. And the median was 32.88.

CLVLF's EV-to-Revenue is ranked better than
53.28% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs CLVLF: 7.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-04), Clinuvel Pharmaceuticals's stock price is $9.765. Clinuvel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.03. Therefore, Clinuvel Pharmaceuticals's PS Ratio for today is 9.52.

Clinuvel Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Clinuvel Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals EV-to-Revenue Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-Revenue

Get a 7-Day Free Trial

51.38

36.91

29.92

9.33

9.29

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	9.33	-	9.29	-

Competitive Comparison of Clinuvel Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's EV-to-Revenue falls into.

Clinuvel Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Clinuvel Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	375.299	/	54.454
	=	6.89

Clinuvel Pharmaceuticals's current Enterprise Value is $375.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $54.45 Mil.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Clinuvel Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	9.765	/	1.026
	=	9.52

Clinuvel Pharmaceuticals's share price for today is $9.765.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $1.03.

Clinuvel Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.